Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Maughan TS Adams RA

    2020-08-18


    [21] Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Ad-dition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet (London, England) 2011 Jun;377(9783):2103–14.
    [22] De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12(6):594–603. [23] Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal 1 \'-hydroxy Midazolam in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol 2012 Jun;23(6):1518–25.
    [24] Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009 Jun;27(16):2622–9.
    [27] Molleví DG, Serrano T, Ginestà MM, Valls J, Torras J, Navarro M, et al. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis 2007 Jun 1;28(6):1241–6.
    [28] Fariña Sarasqueta A, Forte GI, Corver WE, de Miranda NF, Ruano D, van Eijk R, et al. Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer. BMC Cancer 2013;13(1):277. [29] Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MMJ, de Jong D, et al. Deter-mination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005 Aug;23(24):5635–43.
    [30] Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005 Oct;23(30):7518–28.
    [33] Kozak MM, von Eyben R, Pai J, Vossler SR, Limaye M, Jayachandran P, et al. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treat-ment in colorectal cancer. J Clin Pathol 2015 May;68(5):341–5. [34] Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015 Jul;21(7):795–801.
    [35] Baas JM, Krens LL, Guchelaar H-J, Morreau H, Gelderblom H. Concordance of predic-tive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 2011 Sep 8;16(9):1239–49. [36] Mao C, Wu X-Y, Yang Z-Y, Threapleton DE, Yuan J-Q, Yu Y-Y, et al. Concordant anal-ysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary co-lorectal cancer and matched metastases. Sci Rep 2015 Feb 2;5:8065. [37] Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion se-quencing. N Engl J Med 2012 Mar;366(10):883–92.
    [46] Petaccia de Macedo M, Melo FM, Ribeiro HSC, Marques MC, Kagohara LT, Begnami MD, et al. KRAS mutation status is highly homogeneous between areas of the pri-mary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care. Am J Cancer Res 2017 Sep 1;7(9):1978–89.
    [47] Pang X-L, Li Q-X, Ma Z-P, Shi Y, Ma Y-Q, Li X-X, et al. Association between clinico-pathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation. Onco Targets Ther 2017 May 19;10:2645–54.
    [48] Nemecek R, Berkovcova J, Radova L, Kazda T, Mlcochova J, Vychytilova-Faltejskova P, et al. Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy. Onco Targets Ther 2016 Jul 28;9:4695–703.
    [51] Kovaleva V, Geissler A-L, Lutz L, Fritsch R, Makowiec F, Wiesemann S, et al. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their me-tastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. Mol Cancer 2016 Oct 18;15:63.
    [52] Crumley SM, Pepper KL, Phan AT, Olsen RJ, Schwartz MR, Portier BP. Next-generation sequencing of matched primary and metastatic rectal adenocarcinomas demonstrates minimal mutation gain and concordance to colonic adenocarci-nomas. Arch Pathol Lab Med 2016 Jun;140(6):529–35.